Cancer Radiotherapie

metrics 2024

Pioneering insights in oncology and radiology for better patient outcomes.

Introduction

Cancer Radiotherapie, published by Elsevier, is a respected academic journal dedicated to advancing the field of oncology and radiology through original research and comprehensive reviews. With an ISSN of 1278-3218 and an E-ISSN of 1769-6658, the journal serves as a vital platform for disseminating knowledge and innovation in cancer treatment methodologies, specifically focusing on radiotherapy. As of 2023, it holds a Category Quartile of Q3 in both Oncology and Radiology, Nuclear Medicine and Imaging, reflecting its significance within these domains amidst a competitive landscape. Despite its current rankings—205th out of 333 in Radiology and 269th out of 404 in Oncology—it continuously strives to build a reputable presence with contributions that push the boundaries of cancer therapy. Although open access options are not available, the journal is committed to ensuring that valuable insights reach healthcare professionals and researchers worldwide, contributing to improved patient outcomes and advancements in treatment efficacy.

Metrics 2024

SCIMAGO Journal Rank0.41
Journal Impact Factor1.50
Journal Impact Factor (5 years)1.20
H-Index36
Journal IF Without Self1.50
Eigen Factor0.00
Normal Eigen Factor0.26
Influence0.24
Immediacy Index0.20
Cited Half Life4.60
Citing Half Life7.40
JCI0.39
Total Documents2842
WOS Total Citations1225
SCIMAGO Total Citations7687
SCIMAGO SELF Citations2646
Scopus Journal Rank0.41
Cites / Document (2 Years)1.53
Cites / Document (3 Years)1.41
Cites / Document (4 Years)1.24

Metrics History

Rank 2024

Scopus

Radiology, Nuclear Medicine and Imaging in Medicine
Rank #205/333
Percentile 38.44
Quartile Q3
Oncology in Medicine
Rank #269/404
Percentile 33.42
Quartile Q3

IF (Web Of Science)

ONCOLOGY
Rank 259/322
Percentile 19.70
Quartile Q4
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Rank 124/204
Percentile 39.50
Quartile Q3

JCI (Web Of Science)

ONCOLOGY
Rank 246/322
Percentile 23.60
Quartile Q4
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Rank 144/204
Percentile 29.41
Quartile Q3

Quartile History

Similar Journals

Cancer Management and Research

Connecting researchers to redefine cancer care.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Empowering breakthroughs at the intersection of technology and cancer treatment.
Publisher: SAGE PUBLICATIONS INCISSN: 1533-0346Frequency: 1 issue/year

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

Translational Oncology

Transforming Cancer Insights into Clinical Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

International Journal of Clinical Oncology

Empowering Oncology Research for Tomorrow
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

npj Precision Oncology

Leading the Charge in Precision Oncology Research
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

ONCOLOGY

Advancing cancer research through impactful insights.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Oncologie

Fostering dialogue in the dynamic world of oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

PROSTATE

Elevating the standards of prostate care and research.
Publisher: WILEYISSN: 0270-4137Frequency: 16 issues/year

PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

Radiation Oncology Journal

Driving progress in cancer treatment with expert knowledge and innovation.
Publisher: KOREAN SOC THERAPEUTIC RADIOLOGY & ONCOLOGYISSN: 2234-3156Frequency: 4 issues/year

Radiation Oncology Journal, published by the Korean Society of Therapeutic Radiology & Oncology, stands at the forefront of cancer treatment research and innovation within the dynamic fields of oncology and radiology. With a focus on disseminating groundbreaking findings and advancements from 2012 to 2024, this journal aims to foster collaboration among researchers, clinicians, and educators dedicated to improving therapeutic techniques and patient outcomes in the context of radiation therapy. Recognized with a prestigious Q2 ranking in both the Oncology and Radiology, Nuclear Medicine and Imaging categories, it ranks 140th out of 333 in its Scopus category for Medicine Radiology and boasts a 58th percentile placement. While operating on a non-open access basis, the journal remains committed to providing valuable insights and updates to professionals in the field from its base in South Korea. As the landscape of cancer treatment evolves, the Radiation Oncology Journal continues to play a vital role in shaping research trends and enhancing the understanding of radiotherapy's role in comprehensive cancer care.

Journal of Contemporary Brachytherapy

Shaping the future of oncology through accessible brachytherapy research.
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1689-832XFrequency: 6 issues/year

Journal of Contemporary Brachytherapy, published by TERMEDIA PUBLISHING HOUSE LTD, is a distinguished open-access journal dedicated to advancing the field of brachytherapy within the oncology and radiology domains. Since its inception in 2009, the journal has provided a platform for researchers, clinicians, and students to share innovative findings, cutting-edge techniques, and clinical experiences, contributing significantly to evidence-based practices in cancer treatment. With an ISSN of 1689-832X and E-ISSN 2081-2841, the journal has established its presence globally, and it is indexed in Scopus, achieving a commendable standing among its peers—with rankings of #196 in Radiology, Nuclear Medicine, and Imaging and #260 in Oncology for 2023. Notably, it holds a Q3 quartile classification, reflecting its emerging influence in these critical fields. The journal is committed to open science, ensuring that research is accessible to a wide audience, which is particularly vital for the ongoing development of methodologies and the implementation of best practices in brachytherapy. Exploring topics from the technical aspects of brachytherapy procedures to patient management strategies, the Journal of Contemporary Brachytherapy is an essential resource for those looking to stay at the forefront of oncological advancements.